Intraventricular interferon and oral inosiplex in the treatment of subacute sclerosing panencephalitis.
We treated 22 patients with subacute sclerosing panencephalitis (SSPE) with intraventricular alpha-interferon (IFN) and inosiplex PO and followed them for 2 to 54 months. Three deaths occurred. Clinical improvement, demonstrated by decreasing scores on the Neurological Disability Index, occurred in 11/22 (50%); five patients became stable, and the progression rate of the disease decreased in three. The remission rate was significantly higher than untreated controls from the same institution. Patients who had a slowly progressive disease responded best to treatment. Serious side effects were rare. We recommend intraventricular IFN, combined with oral inosiplex, in the treatment of SSPE.
Department of Pediatric Neurology, Hacettepe University, Ankara, Turkey.
K
K
Yalaz
B
B
Anlar
F
F
Oktem
S
S
Aysun
S
S
Ustacelebi
O
O
Gurcay
K
K
Gucuyener
Y
Y
Renda
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D002648:Child; D005260:Female; D006801:Humans; D007276:Injections, Intraventricular; D007542:Inosine Pranobex / Q000008:administration & dosage*; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D013344:Subacute Sclerosing Panencephalitis / Q000188:drug therapy*
D016898:Interferon-alpha; D007542:Inosine Pranobex